Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Surgery Partners Inc (NASDAQ: SGRY) closed the day trading at $20.39 down -3.59% from the previous closing price of $21.15. In other words, the price has decreased by -$3.59 from its previous closing price. On the day, 1.5 million shares were traded. SGRY stock price reached its highest trading level at $21.19 during the session, while it also had its lowest trading level at $20.36.
Ratios:
For a better understanding of SGRY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.91. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 2.22 whereas as Long-Term Debt/Eq ratio is at 2.13.
On December 16, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $30.BofA Securities initiated its Buy rating on December 16, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 29 ’25 when Wayne DeVeydt bought 18,134 shares for $22.05 per share.
Wayne DeVeydt bought 5,627 shares of SGRY for $123,794 on Sep 26 ’25. On Sep 23 ’25, another insider, Wayne DeVeydt, who serves as the former director of the company, bought 25,000 shares for $22.02 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2614189824 and an Enterprise Value of 8068407296. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.81 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 2.493 whereas that against EBITDA is 12.511.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.86, which has changed by -0.31044978 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $33.37, while it has fallen to a 52-week low of $18.87. The 50-Day Moving Average of the stock is -8.40%, while the 200-Day Moving Average is calculated to be -9.73%.
Shares Statistics:
Over the past 3-months, SGRY traded about 1.46M shares per day on average, while over the past 10 days, SGRY traded about 1219810 shares per day. A total of 128.21M shares are outstanding, with a floating share count of 75.98M. Insiders hold about 40.74% of the company’s shares, while institutions hold 73.79% stake in the company. Shares short for SGRY as of 1757894400 were 13218704 with a Short Ratio of 9.04, compared to 1755216000 on 12747748. Therefore, it implies a Short% of Shares Outstanding of 13218704 and a Short% of Float of 21.86.
Earnings Estimates
The market rating for Surgery Partners Inc (SGRY) is a result of the insights provided by 11.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.47, with high estimates of $0.61 and low estimates of $0.32.
Analysts are recommending an EPS of between $1.06 and $0.57 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.01, with 11.0 analysts recommending between $1.65 and $0.69.
Revenue Estimates
11 analysts predict $823.55M in revenue for. The current quarter. It ranges from a high estimate of $839.4M to a low estimate of $803.8M. As of. The current estimate, Surgery Partners Inc’s year-ago sales were $770.4MFor the next quarter, 11 analysts are estimating revenue of $931.12M. There is a high estimate of $951.2M for the next quarter, whereas the lowest estimate is $904.35M.
A total of 11 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.39B, while the lowest revenue estimate was $3.32B, resulting in an average revenue estimate of $3.36B. In the same quarter a year ago, actual revenue was $3.11BBased on 11 analysts’ estimates, the company’s revenue will be $3.68B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.62B.
